Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China
World Journal of Urology · 31.10.2025 · 43 (1)
DOI: 10.1007/s00345-025-06006-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 31.10.2025. Verfasst von Jingwen Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Recent clinical trials (CheckMate 901 and EV-302) have shown that nivolumab plus gemcitabine-cisplatin (N + GC) and enfortumab vedotin plus pembrolizumab (EV + P) significantly improve survival in locally advanced or metastatic urothelial carcinoma (la/mUC). Updated follow-up results from the EV-302 study were presented at the ASCO GU 2025 conference, but the economic feasibility of these therapies remains unclear. This study aims to access the cost-effectiveness of N + GC and EV + P compared to chemotherapy in la/mUC across the US, UK, and China using updated follow-up data from clinical trials. METHODS: This study employed a Markov model included three health states to evaluate health outcomes and costs. Each model cycle spanned 3 weeks with 2 years, 5 years, 10 years. Patients were divided into two subgroups according to cisplatin eligibility. The outcomes were the costs, Quality Adjusted Life Years (QALYs), and Incremental cost-effectiveness ratios (ICERs). RESULTS: For cisplatin-ineligible patients, the 10-year ICERs for EV + P were £136,919/QALY in the UK, $751,897/QALY in the US, and ¥1,158,228/QALY in China. For cisplatin-eligible patients, the 10-year ICERs were £125,441/QALY in the UK, $784,553/QALY in the US, and ¥1,096,445/QALY in China. N + GC demonstrated better cost-effectiveness, with 10-year ICERs of £71,202/QALY in the UK, $183,062/QALY in the US, and ¥259,844/QALY in China. Substantial price reductions were required for both therapies to meet willingness-to-pay thresholds. CONCLUSIONS: While EV + P offered significant survival benefits for la/mUC patients as the first-line therapy, its current pricing makes it economically unfeasible in most settings. N + GC was more cost-effective for cisplatin-eligible patients. Policymakers should consider innovative pricing strategies to ensure equitable access to treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- The School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Quality Management, Ganzhou Fifth People' s Hospital, Ganzhou, Jiangxi, China.
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. liumaobai@126.com.
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. caihongfu31@126.com.
Zitieren
APA
Lin, J., Fu, W., You, C., Song, X., Liu, M., & Cai, H. (2025). Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China. World Journal of Urology, 43(1). https://doi.org/10.1007/s00345-025-06006-4
Vancouver
Lin J, Fu W, You C, Song X, Liu M, Cai H. Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China. World Journal of Urology. 2025;43(1). doi:10.1007/s00345-025-06006-4
BibTeX
@article{Lin2025,
author = {Lin, Jingwen and Fu, Wu and You, Caicong and Song, Xiaobin and Liu, Maobai and Cai, Hongfu},
title = {Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China},
journal = {World Journal of Urology},
year = {2025},
volume = {43},
number = {1},
doi = {10.1007/s00345-025-06006-4}
}
EUVIMED